iBio Inc. | Balance Sheet

Fiscal year is July-June. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Cash & Short Term Investments
4,414.00
3,590.00
9,494.00
23,014.00
8,088.00
15,934
Total Accounts Receivable
1,007.00
205.00
445.00
606.00
175.00
75
Inventories
-
-
-
22.00
26.00
-
Other Current Assets
1,214.00
118.00
182.00
264.00
283.00
276
Total Current Assets
6,635.00
3,913.00
10,121.00
23,906.00
8,572.00
16,285
Net Property, Plant & Equipment
6.00
6.00
13.00
25,574.00
25,589.00
25,152
Intangible Assets
2,713.00
2,575.00
2,360.00
2,092.00
1,823.00
1,620
Other Assets
-
-
-
28.00
26.00
26
Total Assets
9,354.00
6,494.00
12,494.00
51,600.00
36,010.00
43,083
ST Debt & Current Portion LT Debt
-
-
-
170.00
183.00
Accounts Payable
2,401.00
297.00
1,104.00
1,177.00
749.00
Other Current Liabilities
1,885.00
98.00
159.00
944.00
1,081.00
Total Current Liabilities
4,286.00
395.00
1,263.00
2,291.00
2,013.00
Long-Term Debt
-
-
-
25,265.00
25,082.00
Total Liabilities
4,286.00
395.00
1,263.00
27,556.00
27,095.00
Common Equity (Total)
5,068.00
6,099.00
11,231.00
9,937.00
8,914.00
Total Shareholders' Equity
5,068.00
6,099.00
11,231.00
9,937.00
8,914.00
Total Equity
5,068.00
6,099.00
11,231.00
24,044.00
8,915.00
Liabilities & Shareholders' Equity
9,354.00
6,494.00
12,494.00
51,600.00
36,010.00
Accumulated Minority Interest
-
-
-
14,107.00
1.00

About iBio

View Profile
Address
600 Madison Avenue
New York New York 10022
United States
Employees -
Website http://www.ibioinc.com
Updated 07/08/2019
iBio, Inc. operates as a biotechnology company, which focuses on using its proprietary technologies and production facilities to provide product development and manufacturing services to clients, collaborators, and third-party customers as well as developing and commercializing its own product candidates. It operates through the iBio, Inc. and iBio CDMO business segments. The iBio CDMO segment is a subsidiary of the company, which develops and manufactures plant-made pharmaceuticals.